LifeVantage announces Q1 adjusted EPS of 18 cents, falling short of two estimates at 19 cents.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Q1 Revenue Performance: LifeVantage reported Q1 revenue of $47.6 million, falling short of estimates of $54.74 million.
Strategic Acquisition: The company is focused on integrating its recent acquisition of LoveBiome, aiming to lead in the natural GLP-1 activation and microbiome health markets.
Growth Potential: CEO Steve Fife highlighted encouraging trends that could drive growth as they scale operations and leverage strategic investments.
Wellness Ecosystem: LifeVantage is positioned to meet evolving consumer health needs through a comprehensive wellness ecosystem and scientifically validated activation technologies.
Analyst Views on LFVN
Wall Street analysts forecast LFVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFVN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.330
Low
12.00
Averages
12.00
High
12.00
Current: 6.330
Low
12.00
Averages
12.00
High
12.00
About LFVN
LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
